By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences and the Buck Institute for Research on Aging announced today a collaboration to develop mass spectrometry-based tests aimed at improving response to breast cancer therapies.

Under the terms of the deal, Proteome Sciences will support the development of mass spec assays that measure changes in estrogen receptor alpha, a biomarker associated with response to anti-estrogen therapies for breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.